Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

• DOI: 10.1016/j.gendis.2023.04.023
• Publication Date: 2023-06-22T23:58:17Z
• Authors: Meijia Yu; Yiming Wu; Qingfang Li; Weiqi Hong; Yang Yang; Xiaoyi Hu; Yanfei Yang; Tianqi Lu; Xia Zhao; Xiawei Wei
• Keywords: 0301 basic medicine; Medicine (General); Paclitaxel; Tumor-associated macrophages; QH426-470; Targeted therapy; 03 medical and health sciences; R5-920; Ovarian cancer; PLX3397; Full Length Article; Genetics; CSF-1R

Ovarian cancer is the tumor with the highest mortality among gynecological malignancies. Studies have confirmed that paclitaxel chemoresistance is associated with increased infiltration of tumor-associated macrophages (TAMs) in the microenvironment. Colony-stimulating factor 1 (CSF-1) receptor (CSF-1R) plays a key role in regulating the number and differentiation of macrophages in certain solid tumors. There are few reports on the effects of targeted inhibition of CSF-1R in combination with chemotherapy on ovarian cancer and the tumor microenvironment. Here, we explored the antitumor efficacy and possible mechanisms of the CSF - 1R inhibitor pexidartinib (PLX3397) when combined with the first-line chemotherapeutic agent paclitaxel in the treatment of ovarian cancer. We found that CSF-1R is highly expressed in ovarian cancer cells and correlates with poor prognosis. Treatment by PLX3397 in combination with paclitaxel significantly inhibited the growth of ovarian cancer both in vitro and in vivo. Blockade of CSF-1R altered the macrophage phenotype and reprogrammed the immunosuppressive cell population in the tumor microenvironment.